Skip to main content
Clinical Trials/NCT01461330
NCT01461330
Terminated
Not Applicable

Lifestyle Changes in Patients With Type 2 DM and Hypertension: DASH Diet and Exercise Effects

Hospital de Clinicas de Porto Alegre1 site in 1 country40 target enrollmentFebruary 2011
ConditionsBlood Pressure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Blood Pressure
Sponsor
Hospital de Clinicas de Porto Alegre
Enrollment
40
Locations
1
Primary Endpoint
Change from Baseline in Blood Pressure at 4 weeks
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

Data obtained in hypertensive patients without diabetes suggest that increased association of non-pharmacological treatment in patients with diabetes and hypertension may be associated with an improvement in blood pressure control. Despite the beneficial results found, is not yet known the magnitude of the effect of a DASH diet associated with the stimulus of physical activity on BP in patients with type 2 diabetes. The beneficial effects on blood pressure of an additional non-pharmacological intervention to drug therapy may have an even greater impact in patients with treatment-resistant hypertension The aim of this study is to evaluate the effect of changes in lifestyle on blood pressure in patients with type 2 diabetes and hypertension resistant to treatment.

Detailed Description

The aim of this study is to evaluate the effect of changes in lifestyle on blood pressure in patients with type 2 diabetes and hypertension. Secondary objectives are: Assess whether the prescription of a DASH-type diet and encouragement for physical activity through use of pedometers, can improve blood pressure control in patients with type 2 diabetes and hypertension resistant to treatment. Forty type 2 diabetic with resistant hypertension outpatients were included in a randomized clinical trial: treatment 1- DASH diet + encouragement for physical activity through use of pedometer; treatment 2- ADA diet + usual exercises. The duration of each treatment are four weeks. The patients included should have performed Ambulatory Blood Pressure Monitoring (ABPM) to exclude white-coat effect, ie when there are abnormal in the measurement of office blood pressure (equal to or above 140/90 mm Hg) and normal blood pressure by ABPM during the awake period (equal to or below 135/85 mm Hg). Twenty-four hour records with concurrent 24h urinary collections (protein intake estimative), clinical and laboratory evaluation were performed at baseline and after 4 weeks. Serum fatty acids were measured in total lipids by gas chromatography.

Registry
clinicaltrials.gov
Start Date
February 2011
End Date
November 2013
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mirela Jobim de Azevedo

Dr., MD, Associated Professor of Medicine

Hospital de Clinicas de Porto Alegre

Eligibility Criteria

Inclusion Criteria

  • type 2 diabetes
  • Blood pressure ≥140/90 mm Hg
  • ABMP ≥ 135/85 mm Hg

Exclusion Criteria

  • digestive disease with malabsorption
  • diabetic neuropathy with gastroparesis
  • BMI ≥ 40 kg/m²

Outcomes

Primary Outcomes

Change from Baseline in Blood Pressure at 4 weeks

Time Frame: 4 weeks

Ambulatory Blood Pressure Monitoring (ABPM) at baseline and after 4 weeks

Secondary Outcomes

  • Change from Baseline in glucose control at 4 weeks(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials